Genmab A/S (NASDAQ:GMAB) to Post FY2024 Earnings of $0.88 Per Share, William Blair Forecasts

Genmab A/S (NASDAQ:GMAB) – William Blair dropped their FY2024 earnings per share estimates for Genmab A/S in a note issued to investors on Wednesday, April 17th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of $0.88 for the year, down from their prior estimate of $0.89. The consensus estimate for Genmab A/S’s current full-year earnings is $1.06 per share. William Blair also issued estimates for Genmab A/S’s FY2025 earnings at $1.05 EPS.

GMAB has been the topic of several other research reports. Morgan Stanley reiterated an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. Truist Financial reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, March 26th. Citigroup cut Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. BMO Capital Markets raised Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $46.00 to $48.00 in a research report on Friday, February 23rd. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Thursday, April 4th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $48.50.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $28.33 on Friday. Genmab A/S has a fifty-two week low of $26.32 and a fifty-two week high of $42.72. The stock has a market capitalization of $18.73 billion, a PE ratio of 29.51, a price-to-earnings-growth ratio of 2.05 and a beta of 0.99. The business’s 50-day simple moving average is $29.36 and its 200-day simple moving average is $30.34.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The firm had revenue of $675.29 million for the quarter, compared to analysts’ expectations of $678.14 million.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Alliancebernstein L.P. raised its stake in shares of Genmab A/S by 21.0% during the 2nd quarter. Alliancebernstein L.P. now owns 8,187,576 shares of the company’s stock worth $311,210,000 after purchasing an additional 1,420,915 shares in the last quarter. BlackRock Inc. raised its stake in shares of Genmab A/S by 1.6% during the 1st quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after purchasing an additional 86,571 shares in the last quarter. Capital International Investors raised its stake in shares of Genmab A/S by 7.7% during the 1st quarter. Capital International Investors now owns 3,952,446 shares of the company’s stock worth $145,433,000 after purchasing an additional 283,031 shares in the last quarter. Macquarie Group Ltd. raised its stake in shares of Genmab A/S by 11.1% during the 1st quarter. Macquarie Group Ltd. now owns 3,484,632 shares of the company’s stock worth $131,580,000 after purchasing an additional 347,437 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of Genmab A/S by 5.8% during the 1st quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company’s stock worth $120,618,000 after purchasing an additional 183,578 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.